Tag Archives: field

Scientific first allows doctors to ‘see’ radiation treatment in body

Dartmouth began to investigate a scientific phenomenon called the Cherenkov effect in 2011. Our scientists and engineers theorized that by using Cherenkov emissions the beam of radiation could be "visible" to the treatment team. The ability to capture a beam of radiation would show: • how the radiation signals travel through the body • the dose of radiation to the skin • any errors in dosage…

Researchers uncover why combination drug treatment ineffective in cancer clinical trials

Faculty of Medicine & Dentistry researcher Michael Sawyer and his colleagues, including first author Vijaya Damaraju, recently published their findings in the peer-reviewed journal, Clinical Cancer Research. In the ’80s and ’90s, cancer research focused on finding out which proteins "drove" cancers. New drugs targeting these proteins worked well by themselves, and some in the field believed combining the new drugs with the older chemotherapy drugs would work better than either drug by itself. …

Epigenetic changes may explain chronic kidney disease

In a recent Genome Biology paper, Susztak, and her co-corresponding author John Greally from the Albert Einstein College of Medicine, Bronx, NY, found, in a genome-wide survey, significant differences in the pattern of chemical modifications on DNA that affect gene expression in kidney cells from patients with chronic kidney disease versus healthy controls. This is the first study to show that changes in these modifications – the cornerstone of the field of epigenetics – might explain chronic kidney disease. Epigenetics is the science of how gene activity can be altered without actual changes in the DNA sequence. …

Finding antitumor T cells in a patient’s own cancer

In a paper recently published in Clinical Cancer Research, investigators in the lab of Daniel Powell, PhD, at the Perelman School of Medicine, University of Pennsylvania, demonstrated for the first time that a T cell activation molecule can be used as a biomarker to identify rare antitumor T cells in human cancers. The molecule, CD137, is a protein that is not normally found on the surface of resting T cells but its expression is induced when the T cell is activated…